Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes.

Autor: James DE; Global PKPD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Shen T; Former employee Eli Lilly and Company, Indianapolis, Indiana, USA., Geiser JS; Global PKPD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Garhyan P; Global PKPD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Chigutsa E; Global PKPD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.

Publikováno v: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jul; Vol. 13 (7), pp. 1214-1223. Date of Electronic Publication: 2024 May 12.

Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

Autor: Chigutsa, E¹, Long, AJ¹, Wallin, JE² wallinjo@lilly.com

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. Aug2017, Vol. 6 Issue 8, p560-568. 9p.

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.

Autor: Bue-Valleskey JM; 1Eli Lilly and Company, Indianapolis, IN., Kazda CM; 2Lilly France, Neuilly sur Seine, France., Ma C; 1Eli Lilly and Company, Indianapolis, IN., Chien J; 1Eli Lilly and Company, Indianapolis, IN., Zhang Q; 1Eli Lilly and Company, Indianapolis, IN., Chigutsa E; 1Eli Lilly and Company, Indianapolis, IN., Landschulz W; 1Eli Lilly and Company, Indianapolis, IN., Haupt A; 1Eli Lilly and Company, Indianapolis, IN., Frias JP; 3Velocity Clinical Research, Los Angeles, CA.

Publikováno v: Diabetes care [Diabetes Care] 2023 May 01; Vol. 46 (5), pp. 1060-1067.

Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.

Autor: Frias J; Velocity Clinical Research, Los Angeles, CA, USA., Chien J; Eli Lilly and Company, Indianapolis, IN, USA., Zhang Q; Eli Lilly and Company, Indianapolis, IN, USA., Chigutsa E; Eli Lilly and Company, Indianapolis, IN, USA., Landschulz W; Eli Lilly and Company, Indianapolis, IN, USA., Syring K; Eli Lilly and Company, Indianapolis, IN, USA., Wullenweber P; Eli Lilly and Company, Indianapolis, IN, USA., Haupt A; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: haupt_axel@lilly.com., Kazda C; Eli Lilly and Company, Indianapolis, IN, USA.

Publikováno v: The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2023 Mar; Vol. 11 (3), pp. 158-168. Date of Electronic Publication: 2023 Feb 06.

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical Trial.

Autor: Chigutsa E; Eli Lilly and Company, Indianapolis, Indiana, USA., Jordie E; Metrum Research Group, Inc., Tariffville, Connecticut, USA., Riggs M; Metrum Research Group, Inc., Tariffville, Connecticut, USA., Nirula A; Eli Lilly and Company, Indianapolis, Indiana, USA., Elmokadem A; Metrum Research Group, Inc., Tariffville, Connecticut, USA., Knab T; Metrum Research Group, Inc., Tariffville, Connecticut, USA., Chien JY; Eli Lilly and Company, Indianapolis, Indiana, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Mar; Vol. 111 (3), pp. 595-604. Date of Electronic Publication: 2021 Nov 17.